scholarly journals P1669PROGNOSTIC IMPORTANCE OF BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) IN RENAL TRANSPLANTATION

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Agnes Molnar ◽  
Edgar Szkibinszkij ◽  
Lilla Lenart ◽  
Adam Hosszu ◽  
Illes Kovacs ◽  
...  
Keyword(s):  
Neurotrophic Factor ◽  
Ischemia Reperfusion ◽  
Graft Function ◽  
Brain Derived Neurotrophic Factor ◽  
Control Group ◽  
Bdnf Level ◽  
Ischemic Time ◽  
Allele Distribution ◽  
Esrd Patients ◽  
Serum Bdnf

Abstract Background and Aims The prevalence of end-stage renal disease (ESRD) has increased ten times higher in the past twenty years, where renal replacement therapy (dialysis or kidney transplantation (KTx)) is the sole life-saving treatment. KTx is the preferred option as it is associated with improved survival and quality of life as well. Delayed graft function (DGF) is one of the main problems affecting long-term kidney survival. Brain-derived neurotrophic factor (BDNF) signalling pathways play pivotal role in mitigating cerebral ischemia/reperfusion injury (IRI), however the relation of BDNF and IRI in KTx is unknown. The aim of our human clinical study was to explore the relationship between serum BDNF concentration, BDNF gene polymorphism and renal graft function after KTx. Method Study characteristics: We enrolled 59 ESRD patients with average age of 54.8±12 years who received KTx. Proportion of male patients was 57%. Average cold ischemic time was 927±310 min, warm ischemic time was 54.5±39 min. DGF occurred in 5 cases. Baseline triple immunosuppression therapy consisted of tacrolimus, mycophenolate or everolimus, and prednisolone. Until now, 44 patients completed the 2 years follow-up. For a comparable control group, we collected blood samples from 79 healthy volunteers with average age of 53.9±16 years and with male gender proportion of 52%. Serum BDNF, creatinine, blood urea nitrogen, haemoglobin, blood glucose level and thrombocyte numbers were measured before KTx and 1 week, 1-, 3-, 6 months, and 1-, 2 years after transplantation, as well as in controls. GFR was estimated based on the CKD-EPI formula. BDNF Val66Met polymorphism was determined by PCR-RFLP. Results There was no difference in genotype or allele distribution between any of the groups, and no correlation could be observed between serum BDNF and different genotypes either. Serum BDNF level was lower in ESRD patients than healthy controls (p=0.03). There was a weak correlation and marginal significance (p=0.056) between eGFR and serum BDNF level in controls, while in KTx recipients this correlation reached higher significance (p=0.01). Above median BDNF values at 1 month after KTx were predictive for better graft function during the 2 observed years. Conclusion Our preliminary human study proposes that BDNF could be a novel biomarker of posttransplant graft function, however further clinical studies with significantly larger population are definitely needed to confirm these results.

Increased serum brain-derived neurotrophic factor levels following electroconvulsive therapy or antipsychotic treatment in patients with schizophrenia

2016 ◽  
Vol 36 ◽  
pp. 23-28 ◽  
Author(s):  
J. Li ◽  
F. Ye ◽  
W. Xiao ◽  
X. Tang ◽  
W. Sha ◽  
...  
Keyword(s):  
Electroconvulsive Therapy ◽  
Neurotrophic Factor ◽  
Brain Derived Neurotrophic Factor ◽  
Longitudinal Change ◽  
Psychotic Symptoms ◽  
Control Group ◽  
Antipsychotic Treatment ◽  
Bdnf Level ◽  
Baseline Serum ◽  
Serum Bdnf

AbstractBackgroundMany schizophrenia patients experience residual symptoms even after treatment. Electroconvulsive therapy (ECT) is often used in medication-resistant schizophrenia patients when pharmacologic interventions have failed; however, the mechanism of action is unclear. Brain-derived neurotrophic factor (BDNF) levels are reduced in drug-naive, first-episode schizophrenia and are increased by antipsychotic treatment. We tested the hypothesis that ECT increases serum BDNF levels by measuring BDNF concentrations in schizophrenia patients before and after they received ECT.MethodsA total of 160 patients with schizophrenia were examined. The ECT group (n = 80) was treated with antipsychotics and ECT (eight to 10 sessions administered every other day). The drug therapy group (n = 80) received only antipsychotic treatment. A control group (n = 77) was recruited that served as the baseline for comparison.ResultsBaseline serum BDNF level in ECT group was lower than in controls (9.7 ± 2.1 vs. 12.4 ± 3.2 ng/ml; P < 0.001), but increased after ECT, such that there was no difference between the two groups (11.9 ± 3.3 vs. 12.4 ± 3.2 ng/ml; P = 0.362). There was no correlation between patients’ Positive and Negative Syndrome Scale (PANSS) score and serum BDNF level before ECT; however, a negative correlation was observed after ECT (total: r = −0.692; P < 0.01). From baseline to remission after ECT, serum BDNF level increased (P < 0.001) and their PANSS score decreased (P < 0.001). Changes in BDNF level (2.21 ± 4.10 ng/ml) and PANSS score (28.69 ± 14.96) were positively correlated in the ECT group (r = 0.630; P < 0.01).ConclusionsBDNF level was lower in schizophrenia patients relative to healthy controls before ECT and medication. BDNF level increased after ECT and medication, and its longitudinal change was associated with changes in patients’ psychotic symptoms. These results indicate that BDNF mediates the antipsychotic effects of ECT.

scholarly journals Elevated levels of serum, but not salivary, brain-derived neurotrophic factor following mild traumatic brain injury in collegiate athletes post return-to-play

2019 ◽  
Vol 3 ◽  
pp. 205970021989410
Author(s):  
Taylor R Susa ◽  
Ryan D Brandt ◽  
Keara J Kangas ◽  
Catherine E Bammert ◽  
Erich N Ottem ◽  
...  
Keyword(s):  
Traumatic Brain Injury ◽  
Brain Injury ◽  
Mild Traumatic Brain Injury ◽  
Neurotrophic Factor ◽  
Collegiate Athletes ◽  
Brain Derived Neurotrophic Factor ◽  
Return To Play ◽  
Control Group ◽  
The Relationship ◽  
Serum Bdnf

Brain-derived neurotrophic factor (BDNF) helps restore neuronal function following mild traumatic brain injury. BDNF levels can be obtained in blood serum and more recently in saliva. However, the relationship between serum and salivary BDNF is poorly understood—especially in relation to alterations in BDNF levels following mild traumatic brain injury. In this study, serum and salivary BDNF were collected from a sample of 42 collegiate student athletes. Half of the participants were recently cleared by a physician and/or an athletic trainer to return-to-play after experiencing a sports-related concussion. The other half had not experienced a concussion within the past year and were matched by age, sex, sport, and time of sample. Results suggest that incidences of depression, anxiety, and stress were all elevated in the concussion group, relative to the control participants. When controlling for stress-related negative affect, serum BDNF was elevated in the concussion group. However, there was no difference in salivary BDNF. Serum and salivary BDNF were uncorrelated across the entire sample. Yet, these measures of BDNF were correlated in the concussion group, but not the control group. In sum, serum BDNF is elevated in concussion post return-to-play; however, further research is needed to explore the utility of salivary BDNF following concussion.

scholarly journals Brain-Derived Neurotrophic Factor and Its Serum Levels in Schizophrenic Patients

Folia Medica ◽  
2014 ◽  
Vol 56 (1) ◽  
pp. 20-23 ◽  
Author(s):  
Yvetta A. Koeva ◽  
Stefan T. Sivkov ◽  
Valentin H. Akabaliev ◽  
Roumiana Y. Ivanova ◽  
Tania I. Deneva ◽  
...  
Keyword(s):  
Neurotrophic Factor ◽  
Statistical Significance ◽  
Serum Levels ◽  
Brain Derived Neurotrophic Factor ◽  
Control Group ◽  
Significant Difference ◽  
Schizophrenic Patients ◽  
The Difference ◽  
Student’S T ◽  
Serum Bdnf

ABSTRACT INTRODUCTION: Neurotrophins have an important role in regulating the development and maintenance of the peripheral and central nervous systems’ function. Thus, the neurotrophin hypothesis of schizophrenia has postulated that the changes in the brain of schizophrenic patients are the result of disturbances of developing processes involving these molecules. AIM: We analyse in the present study the changes in the serum levels of brain-derived neurotrophic factor (BDNF) in schizophrenic patients as possible epiphenomena of underlying alterations of the neurotrophic factor in central nervous system, reflecting its role in the pathophysiology of schizophrenia. PATIENTS AND METHODS: Twenty-one schizophrenic patients satisfying the DSM-IV criteria for diagnosis of schizophrenia were enrolled in the study. The control group consisted of 28 age-matched mentally healthy subjects. Serum BDNF levels were determined in patients and normal controls using ELISA (Chemicon International, USA & Canada). The data were analyzed statistically with Student’s t- test in SPSS 9.0. RESULTS: The serum BDNF levels were lower in the schizophrenic patients than in the control subjects, reaching statistically significant difference (t = 2.72, p = 0.009). Female patients had lower serum BDNF levels than the male patients but the difference fell short of statistical significance (t = 0.1, p = 0.9). CONCLUSIONS: The BDNF reduction in serum indicates a potential deficit in neurotrophic factor release in patients with schizophrenia and support the concept that BDNF might be associated with schizophrenia

Serum and Aqueous Humor Levels of Brain-Derived Neurotrophic factor in Patients with Primary Open-Angle Glaucoma and Normal Tension Glaucoma

2021 ◽  
Author(s):  
Yu Wan Cha ◽  
Seong Taeck Kim
Keyword(s):  
Aqueous Humor ◽  
Neurotrophic Factor ◽  
Primary Open Angle Glaucoma ◽  
Open Angle Glaucoma ◽  
Brain Derived Neurotrophic Factor ◽  
Normal Tension Glaucoma ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Group ◽  
Open Angle ◽  
Serum Bdnf

Abstract PurposeThis study designed to compare the levels of brain-derived neurotrophic factor (BDNF) in the serum and aqueous humor (AH) of patients with primary open-angle glaucoma (POAG) and normal-tension glaucoma (NTG).MethodsThis prospective, observational study consists of 30 patients with POAG, 30 patients with NTG, and 30 healthy controls. The serum and AH BDNF levels were assessed using an enzyme-linked immunosorbent assay.ResultsBDNF levels in serum and AH were markedly lower in the glaucoma groups (POAG and NTG) than in the control group (p < 0.05). When comparing the NTG and POAG groups, the average serum BDNF level was significantly lower in the NTG group than in the POAG group (p < 0.05). The difference in the mean BDNF levels in AH between the POAG and NTG groups was not statistically significant. (p = 0.538).ConclusionWe confirmed that serum BDNF levels were lower in patients with NTG than in those with POAG. BDNF could be a causative systemic biomarker in NTG.

scholarly journals Effect of Yoga on Pain, Brain-Derived Neurotrophic Factor, and Serotonin in Premenopausal Women with Chronic Low Back Pain

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Moseon Lee ◽  
Woongjoon Moon ◽  
Jaehee Kim
Keyword(s):  
Low Back Pain ◽  
Back Pain ◽  
Chronic Low Back Pain ◽  
Neurotrophic Factor ◽  
Premenopausal Women ◽  
Brain Derived Neurotrophic Factor ◽  
Control Group ◽  
Low Back ◽  
Yoga Group ◽  
Serum Bdnf

Background. Serotonin and brain-derived neurotrophic factor (BDNF) are known to be modulators of nociception. However, pain-related connection between yoga and those neuromodulators has not been investigated. Therefore, we aimed to evaluate the effect of yoga on pain, BDNF, and serotonin.Methods. Premenopausal women with chronic low back pain practiced yoga three times a week for 12 weeks. At baseline and after 12 weeks, back pain intensity was measured using visual analogue scale (VAS), and serum BDNF and serotonin levels were evaluated. Additionally, back flexibility and level of depression were assessed.Results. After 12-week yoga, VAS decreased in the yoga group (P<0.001), whereas it increased (P<0.05) in the control group. Back flexibility was improved in the yoga group (P<0.01). Serum BDNF increased in the yoga group (P<0.01), whereas it tended to decrease in the control group (P=0.05). Serum serotonin maintained in the yoga group, while it reduced (P<0.01) in the control group. The depression level maintained in the yoga group, whereas it tended to increase in the control group (P=0.07).Conclusions. We propose that BDNF may be one of the key factors mediating beneficial effects of yoga on chronic low back pain.

scholarly journals ANXIOUS-DEPRESSIVE SYMPTOMATOLOGY AND BRAIN-DERIVED NEUROTROPHIC FACTOR LEVEL IN PATIENTS WITH TENSION HEADACHE

2017 ◽  
Vol 34 (6) ◽  
pp. 34-39
Author(s):  
K V Tyan ◽  
P P Kalinsky ◽  
A V Rakitova
Keyword(s):  
Blood Serum ◽  
Neurotrophic Factor ◽  
Depressive Symptomatology ◽  
Tension Headache ◽  
Brain Derived Neurotrophic Factor ◽  
Test System ◽  
Serotoninergic System ◽  
Bdnf Level ◽  
Group 2 ◽  
Serum Bdnf

Aim. To study the correlation between the blood serum brain-derived neurotrophic factor (BDNF) level and the manifestation of anxious-depressive symptomatology in patients with tension headache. Materials and methods. The study involved 82 patients with tension headache. The method of immune-enzyme assay with test-system ELISA kit was used to measure the blood serum BDNF concentration. Results. The BDNF level in patients with episodic infrequent and frequent tension headaches was comparable with the group of control. Among patients with chronic tension headache, decrease in BDNF level as compared to group 1, group 2 and the control was revealed. The BDNF level is changed, depending on the duration and intensiveness of tension headache. Conclusions. Chronic tension headache causes exhaustion of not only mediator, but of neurotrophic systems of the brain as well. Blood serum BDNF concentration measured permits to assess activity of cerebral neuroplastic processes and to choose neurotrophic therapy for a more rapid triggering of serotoninergic system and arresting of anxious-depressive syndrome.

scholarly journals Correlation between Serum Brain-Derived Neurotrophic Factor Level and Depression Severity in Psoriasis Vulgaris Patients

2019 ◽  
Vol 7 (4) ◽  
pp. 583-586 ◽  
Author(s):  
Muhammad Sjahrir ◽  
Irma Damayanti Roesyanto-Mahadi ◽  
Elmeida Effendy
Keyword(s):  
Negative Correlation ◽  
Neurotrophic Factor ◽  
Psoriasis Vulgaris ◽  
Severity Index ◽  
Brain Derived Neurotrophic Factor ◽  
Enzyme Linked Immunosorbent Assay ◽  
Depression Severity ◽  
Bdnf Level ◽  
Cross Sectional ◽  
Serum Bdnf

BACKGROUND: Psoriasis vulgaris is a chronic inflammatory skin disorder that can lead to depression. There is a similarity in neurotrophic substance in the pathogenesis of psoriasis and depression; it’s called brain-derived neurotrophic factor (BDNF). BDNF level imbalance potentially affects the severity of psoriasis and depression. AIM: This study aims to know the correlation between serum BDNF level and depression severity in psoriasis vulgaris patient and also the correlation between serum BDNF level and psoriasis vulgaris severity. METHODS: This is an analytical cross-sectional study that 23 psoriasis vulgaris patients participated. All participants have performed serum BDNF level examination with enzyme-linked immunosorbent assay (ELISA). Depression severity assessed with Beck depression inventory-II (BDI-II) and psoriasis severity assessed with psoriasis area and severity index. Correlation between all variables was analysed with Spearman’s correlation test. RESULTS: Serum BDNF level and depression severity are a strongly negative correlation in psoriasis vulgaris patients (r = -0.667 with significant value p = 0.001). There is a moderate negative correlation between serum BDNF level with psoriasis vulgaris severity (r = -0.595 with significant value p = 0.003). CONCLUSION: In psoriasis vulgaris patients, a low level of serum BDNF may increase depression severity and psoriasis vulgaris severity.

scholarly journals Relationship of brain-derived neurotrophic factor, malondialdehyde, and 8-Hydroxy 2-Deoxyguanosine with post-ischemic stroke depression

2020 ◽  
Vol 14 (1) ◽  
pp. 41-46
Author(s):  
Yuliarni Syafrita ◽  
Darwin Amir ◽  
Restu Susanti ◽  
I Fadhilah
Keyword(s):  
Ischemic Stroke ◽  
Acute Stroke ◽  
Neurotrophic Factor ◽  
Brain Derived Neurotrophic Factor ◽  
Bdnf Level ◽  
Post Stroke ◽  
Depression Group ◽  
Post Stroke Depression ◽  
Relationship Of ◽  
Serum Bdnf

ABSTRACT A few studies have shown that serum brain-derived neurotrophic factor (BDNF) level in post-stroke depression is highly correlated with memory and neuropsychiatric disturbances. Objective: This study aimed to elucidate the relationship of serum BDNF, malondialdehyde (MDA), and 8-Hydroxy 2-Deoxyguanosine (8-OhdG) levels in acute stroke cases with one-month post-stroke depression. Methods: An observational study was conducted of 72 post-ischemic stroke patients in the Neurology ward of the Dr. M. Djamil Hospital, Padang, West Sumatra, Indonesia. Acute stroke (< 48 hours) serum BDNF, MDA, and 8-OhdG levels were measured using ELISA. Based on observations using the Hamilton Depression Rating Scale conducted one month after stroke, respondents were divided into two groups: with and without depression. The mean serum level was analyzed using the t-test and Mann-Whitney test, while differences in basic characteristics were analyzed using the Chi-square test. Multivariate analysis was conducted to determine the most significant factor associated with post-stroke depression. The error rate was set at 5%. Results: BDNF levels in acute stroke were significantly lower in the depression group than in the non-depression group (p < 0.05). MDA and 8-OhdG levels in acute stroke were higher in the depression group (p < 0.05). BDNF level during acute stroke was negatively correlated with post-stroke depression, while, conversely, acute stroke MDA and 8-OhdG levels were positively correlated with depression. Conclusion: BDNF had a negative correlation, while MDA and 8-OhdG had a positive correlation, with depression one-month post-stroke. 8-OhdG was the most influential factor in post-stroke depression.

scholarly journals Effects of Virtual Rehabilitation and Constraint Induced Movement Therapy on Brain Derived Neurotrophic Factor Mediated Motor Improvement in Stroke Patients

2019 ◽  
Vol 10 (1) ◽  
pp. 30-34
Author(s):  
Aiman Farogh Anjum ◽  
Humaira Fayyaz Khan ◽  
Noman Sadiq ◽  
Abdul Samad ◽  
Ghazala Jawwad ◽  
...  
Keyword(s):  
Upper Limb ◽  
Neurotrophic Factor ◽  
Brain Derived Neurotrophic Factor ◽  
Control Group ◽  
Study Group ◽  
Stroke Patients ◽  
Control Groups ◽  
Virtual Rehabilitation ◽  
Constraint Induced Movement Therapy ◽  
Serum Bdnf

Objectives: To carry out a comparison between serum BDNF levels as well as enhancement in upper limb motor function in terms of gross movement, pinch, grip, primary grasp, pre and post intervention in the study and control groups. Study design And Setting: It was a Randomized Control Study conducted from March 2015 to March 2016 at Holy Family Hospital Rawalpindi in collaboration with the Multidisciplinary research laboratory at Islamic International Medical College, Rawalpindi. Methodology: In this study; forty stroke patients were randomly designated to either the study group or the control group. Upper limb activity capability which was quantified by Action Research Arm Test (ARAT) and serum Brain Derived Neurotrophic Factor (BDNF) was measured in both control and study group. The control group underwent traditional upper limb physiotherapy for 16 sessions. The study group underwent Constraint Induced Movement Therapy for the upper limb in combination with the use of motion capture video gaming technology for 16 sessions each of twenty minutes duration. Before and after completion of intervention sessions; ARAT and serum BDNF were measured and compared in both control and study groups. Results: Serum BDNF levels was significantly improved in study group as compare to control group (p<0.001). ARAT showed significant improvement in study group participants as compare to control groups (p<0.001). Conclusion: Virtual rehabilitation was an efficacious method for Neuroplastic enhancement in stroke patients

Sign in / Sign up

Export Citation Format

Share Document